JAAHA Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gassel, A. D.
Right arrow Articles by Cox, S. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gassel, A. D.
Right arrow Articles by Cox, S. K.
Journal of the American Animal Hospital Association 42:212-217 (2006)
© 2006 American Animal Hospital Association

Disposition of Deracoxib in Cats After Oral Administration

Adam D. Gassel, DVM, BS, Karen M. Tobias, DVM, MS, Diplomate ACVS and Sherry K. Cox, MS, PhD

From the Departments of Small Animal Clinical Sciences (Gassel, Tobias, Cox) and Comparative Medicine (Cox), College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee 37996-4544.

The pharmacokinetics of deracoxib in seven healthy cats were determined following a single oral (1 mg/kg) dose. Minimal variability among cats was found for all estimated pharmacokinetic variables. Terminal half-life (t1/2) was 7.9 hours. The mean maximum concentration (Cmax) was 0.28 µg/mL and was measured 3.64 hours after drug administration. Deracoxib was not detectable in the plasma after 60 hours. The compounded liquid formula was accepted readily, and no adverse effects were observed. Further studies are needed to determine the efficacy and safety of deracoxib after acute and chronic use in the cat.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Animal Hospital Association.